A new study using brain imaging shows, for the first time, how ketamine acts on specific receptors in the brain. Patients with treatment-resistant depression show an improvement in their symptoms.
Ketamine continues to attract scientific attention in the treatment of treatment-resistant depression. This is particularly true in cases where patients do not respond to conventional therapies. New research suggests that this substance may offer significant clinical benefits, even in the most treatment-resistant stages of the disease.
What do the statistics say about treatment-resistant depression?
Interest in this approach arises in a context where treatment-resistant depression continues to pose a significant challenge in clinical practice. It is estimated that approximately 30% of people with depression develop treatment-resistant depression. In other words, a significant proportion do not respond adequately to traditional antidepressants.
What do these new images of the human brain reveal?
In this study, conducted by the Advanced Medical Research Center (AMRC) at Yokohama City University (YCU) in Japan, researchers used advanced brain imaging techniques to directly observe the effects of ketamine on the human brain. The analysis focused on AMPAR receptors, proteins that are essential for communication between neurons and for synaptic plasticity processes. The images made it possible to track changes in these receptors involved in communication between neurons, particularly in regions associated with mood and the reward system.
The study was subsequently published in the scientific journal *Molecular Psychiatry* on March 5, 2026. The results indicate that these changes are specific to certain regions of the brain and are strongly correlated with a reduction in depressive symptoms. This is one of the first direct demonstrations in humans of the molecular mechanisms associated with ketamine’s antidepressant effect.
Nevertheless, the researchers emphasize that further studies are needed. On the one hand, to understand the long-term effects. On the other hand, to identify which patients benefit the most.
Despite these limitations, these findings underscore ketamine’s potential as a treatment option for treatment-resistant depression, while also contributing to a better understanding of the biological mechanisms involved in the response to treatment.
Learn more about The Clinic of Change’s psychedelic-assisted programs and treatments HERE.
